Seminars in Hematology
Volume 47, Issue 2 , Pages 148-155 , April 2010

Rituximab in High-Grade Lymphoma

  • Carsten Zwick
    • ,
  • Niels Murawski
    • ,
  • Michael Pfreundschuh

      Affiliations

    • Corresponding Author InformationAddress correspondence to Michael Pfreundschuh, MD, Klinik für Innere Medizin I, Saarland University Medical School, D-66421 Homburg (Saar), Germany
    • ,
  • German High-Grade Non-Hodgkin Lymphoma Study Group

References 

  1. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–1493
  2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006
  3. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290–1297
  4. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol. 2000;18:3025–3030
  5. Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med. 1995;332:1045–1051
  6. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796–2802
  7. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst. 2001;93:22–30
  8. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol. 2002;20:4413–4419
  9. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor- prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472–2479
  10. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255–1262
  11. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287–1295
  12. Betticher DC, Martinelli G, Radford JA, et al. Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006;17:1546–1552
  13. Olivieri A, Santini G, Patti C, et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Ann Oncol. 2005;16:1941–1948
  14. Vitolo U, Liberati AM, Cabras MG, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial. Haematologica. 2005;90:793–801
  15. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641
  16. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927–1932
  17. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  18. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–4126
  19. Pfreundschuh M, Truemper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391
  20. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033
  21. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003;101:949–954
  22. Van der Kolk LE, Evers LM Omene C, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia. 2002;16:1735–1744
  23. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634–641
  24. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664–4669
  25. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91:176–183
  26. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptordependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659–1669
  27. Schmitz R, Nickelsen M, Ziepert M, et al. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. ASH Annual Meeting Abstracts. 2009;22:404;114
  28. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641
  29. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116
  30. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin‘s lymphoma [abstract 8506]. J Clin Oncol. 2009;27:15s
  31. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127
  32. Reiser M, Wenger M, Nickenig C, et al. Serum levels and pharmacokinetics of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial [abstract]. J Clin Oncol. 2006;24:430s
  33. Poeschel V, Nickelsen M, Hänel M, et al. Dose-dense rituximab in combination with bi-weekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma: results of phase I/II and pharmacokinetic study of the German High-grade Non-Hodgkin Lymphoma Study Group. Blood. 2006;108:774a–775a
  34. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–1545
  35. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16:3264–3269
  36. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982;60:693–697
  37. De Lord C, Newland AC, Linch DC, Vaughan HB, Vaughan HG. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. Hematol Oncol. 1992;10:81–86
  38. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–122
  39. Soussain C, Souleau B, Gabarre J, et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma (Results of a single-centre study of 65 patients). Leuk Lymphoma. 1999;33:543–550
  40. Sweetenham JW, Johnson PW. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:2766
  41. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–1176
  42. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995;13:1734–1741
  43. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11:1573–1582
  44. Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood. 1990;76:1293–1298
  45. Cortelazzo S, Rambaldi A, Rossi A, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol. 2001;114:333–341
  46. Atta J, Chow KU, Weidmann E, et al. Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2007;48:349–356
  47. Reiser M, Josting A, Dias WP, et al. Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1999;33:305–312
  48. Moskowitz C, Hamlin PA, Horwitz SM, et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy-confirmed abnormal interim restaging PET scan improves outcome of patients with advanced stage DLBCL [abstract]. Blood. 2006;108:161a
  49. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688
  50. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine and cisplatin in combination wirh rituximab as salvage treatment patients with relapsed or refractory aggressive non-Hodgkin‘s lymphoma. Cancer Invest. 2006;24:593–600
  51. Vellenga E, van Putten WL, 't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111:537–543
  52. Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma followed by autologous stem cell transplantation [abstract]. J Clin Oncol. 2009;27:436s
  53. Glass B, Borgerding A, Ziepert M, et al. Outcome of elderly patients with DLBCL failing R-CHOP. The role of rituximab and high dose therapy in second line treatment. A retrospective analysis from the RICOVER 60 trial. [abstract]. ASH Annual Meeting Abstracts. 2009;22:3714;114
  54. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93:1829–1836
  55. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18:1363–1368
  56. Van Oers M, Van Glabekke M, Baila L, Giurgia L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin‘s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract]. Am Soc Hematol. 2008;836
  57. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with R-FCM in patients with refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003–4008
  58. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004;103:4416–4423
  59. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin‘s lymphoma. J Clin Oncol. 2002;20:4261–4267

 Financial disclosure: M.P. is on the Roche Mabthera Advisory Board and has received unrestricted grants from Roche.

PII: S0037-1963(10)00009-0

doi: 10.1053/j.seminhematol.2010.01.008

Seminars in Hematology
Volume 47, Issue 2 , Pages 148-155 , April 2010

Article Tools

* Image Usage & Resolution